Clinical trials: Lymphatic Malformations
Lymphedema
International Lymphatic Disease and Lymphedema Registry
The purpose of the International Lymphatic Disease and Lymphedema Patient Registry and Biorepository is to collect health information in order to study the disease classification, natural history, and impact of Lymphatic Disease…
- Trial name
- NCT01336790
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Stanford University
CCM, Cavernoma
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy.
- Conditions
- CCM, Cavernoma, Cerebral Cavernous Malformation, Cerebral Cavernous Malformations 1
- Trial name
- NCT03652181
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Chicago
Lymphedema, Lymphatic Disorders
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
The purpose of this study is to demonstrate the feasibility of near-infrared fluorescence imaging in subjects with acquired or hereditary lymphedema, in subjects with lipidema and other lymphovascular disorders and in normal…
- Conditions
- Lymphedema, Lymphatic Disorders, Lipedema, Vascular Malformation
- Trial name
- NCT00833599
- Testing
- NIRFLI with ICG
- Where
- 3 sites in United States
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Cavernous Malformation, Cerebral
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
Cerebral cavernous malformation (CCM) is a common vascular abnormality of the brain, affecting 0.1%-0.5% of people. It often causes recurrent brain hemorrhages, epilepsy, and neurological impairments, with surgery being the main…
- Trial name
- CCM-DS01 (NCT07026604)
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tiantan Hospital
Lymphangiomatosis, Lymphedema
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Background: Lymphatics are a type of vessel, similar to arteries and veins. Lymphatic disorders happen when these vessels don t work properly.
- Conditions
- Lymphangiomatosis, Lymphedema, Lymphangiectasia, Pulmonary Lymphangiectasia
- Trial name
- NCT02156115
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
DiGeorge Anomaly
Serum-Free Thymus Transplantation in DiGeorge Anomaly
The study purpose is to determine if thymus tissue cultured in a serum-free (SF) solution is a safe and effective treatment for atypical and typical complete DiGeorge anomaly. [Funding Source - FDA OOPD]
- Trial name
- SerumFree (NCT00849888)
- Testing
- Serum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression
- Volunteers
- 2 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Hereditary Hemorrhagic Telangiectasia, Nosebleeds
Sirolimus for Nosebleeds in HHT
This pilot study is to determine the safety and efficacy of oral sirolimus (blood trough level 6-10ng/ml) in patients with HHT that are experiencing moderate or severe epistaxis.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Nosebleeds, Epistaxis
- Trial name
- NCT05269849
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Angiodysplasia, Vascular Malformations
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
The purpose of this study is to determine whether 40 mg octreotide long-acting release intramuscular every 28 days is effective in the treatment of patients with refractory anemia due to gastrointestinal angiodysplasias.
- Conditions
- Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage, Anemia
- Trial name
- OCEAN (NCT02384122)
- Testing
- Octreotide
- Where
- 12 sites in Netherlands
- Volunteers
- 62 people
- Sponsor
- Radboud University Medical Center
DiGeorge Syndrome, 22q11.2 Deletion Syndrome
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people.
- Trial name
- NCT00556530
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Albert Einstein College of Medicine
22q11 Deletion Syndrome
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
The purpose of the present trial is to investigate the effects of omega-3 PUFAs in individuals aged 12-26 years with 22q11DS at ultra-high risk for developing a first episode of psychosis.
- Trial name
- NCT02070211
- Testing
- omega-3 PUFAs, Standard care
- Where
- Holy See
- Volunteers
- 80 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Cerebral Cavernous Malformation, Intracerebral Hemorrhage
CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
The aim of this prospective study is to reveal the natural history of symptomatic hemorrhage in adult patients with cerebral cavernous malformation with the goal of informing the treatment plan.
- Trial name
- CHOCOOATE (NCT02946866)
- Where
- 8 sites in South Korea
- Volunteers
- 228 people
- Sponsor
- Seoul National University Hospital
Tuberous Sclerosis Complex, Lymphangioleiomyomatosis
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
- Trial name
- NCT06160310
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- David M. Ritter
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT)…
- Trial name
- NCT01408732
- Testing
- Sclerotherapy, Standard Treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Minnesota
Mevalonic Aciduria, Mevalonate Kinase Deficiency
Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Participants wanted for study of mevalonate kinase deficiency (MKD), mevalonic aciduria, or hyperimmunoglobulinemia with periodic fever syndrome (HIDS).
- Conditions
- Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary
- Trial name
- NCT00260299
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Oregon Health and Science University
22q.11.2 Deletion/Duplication
Non-Invasive Chromosomal Evaluation of 22q11.2
This study is being conducted to develop and evaluate a cell-free fetal DNA test (Harmony) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.
- Trial name
- 22Q (NCT02541058)
- Where
- Belgium
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Cindy Cisneros
Congenital Disorders
Prevalence and Clinical Spectrum of the 22q11 Deletion
The purpose of this project is to conduct population based surveillance for prenatally diagnosed congenital defects amount residents of the five counties to: improve the comprehensiveness of the Metropolitan Atlanta Congenital…
- Trial name
- NCT00267397
- Where
- United States
- Sponsor
- Children's Healthcare of Atlanta